Amphastar Pharmaceuticals, Inc. 8-K

What Happened Amphastar Pharmaceuticals, Inc. (AMPH) announced that International Medication Systems, Limited (“IMS”), its subsidiary, received a Warning Letter from the U.S. Food and Drug Administration on July 2, 2026. The Warning Letter follows an FDA inspection of IMS’s South El Monte, California drug manufacturing facility in December 2025 and cites violations of current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals noted on an FDA Form 483.

Key Details

• Warning Letter date: July 2, 2026; inspection occurred in December 2025 and resulted in a Form 483.
• Cited issues: investigation procedures, environmental monitoring and handling procedures, and manufacturing equipment.
• Operational status: IMS continues to manufacture and supply products from the South El Monte facility while implementing corrective actions and a remediation plan.
• Requested actions: FDA asked IMS to submit an initial response within 15 working days, perform a risk assessment, and provide a remediation plan. The letter does not direct a shutdown or require an additional recall (subject to third-party verification).

Why It Matters For investors, an FDA Warning Letter signals regulatory deficiencies that the company must correct and that could lead to further enforcement if not resolved. While IMS remains operational and Amphastar is implementing fixes, the company says it cannot assure the FDA will accept its response or when the matters will be resolved. Potential impacts include regulatory action, supply disruptions, or increased compliance costs, which could affect Amphastar’s operations and financial results. The company is evaluating the business impact and has included standard forward-looking statement cautions in the filing.